Results 271 to 280 of about 131,333 (298)

Immunogenic cell death in cancer and infectious disease

Nature Reviews Immunology, 2016
Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of exogenous or mutated antigens explains why infected cells and malignant cells can initiate an adaptive immune response provided that the cells also emit adjuvant signals as a consequence of cellular stress and death.
Lorenzo Galluzzi, Aitziber Buque, Oliver Kepp   +2 more
exaly   +3 more sources

The inducers of immunogenic cell death for tumor immunotherapy

Tumori Journal, 2018
Immunotherapy is a promising treatment modality that acts by selectively harnessing the host immune defenses against cancer. An effective immune response is often needed to eliminate tumors following treatment which can trigger the immunogenicity of dying tumor cells.
openaire   +2 more sources

eIF2α phosphorylation as a biomarker of immunogenic cell death

Seminars in Cancer Biology, 2015
Cancer cells exposed to some forms of chemotherapy and radiotherapy die while eliciting an adaptive immune response. Such a functionally peculiar variant of apoptosis has been dubbed immunogenic cell death (ICD). One of the central events in the course of ICD is the activation of an endoplasmic reticulum (ER) stress response.
Oliver Kepp, Michaela Semeraro, José Manuel Bravo-San Pedro, Norma Bloy, Aitziber Buqué, Xing Huang, Heng Zhou, Laura Senovilla, Guido Kroemer, Lorenzo Galluzzi   +9 more
openaire   +2 more sources

CX3CL1: a key switch of cell death immunogenicity

Trends in Cancer
CX3CL1 (fractalkine) is a unique chemokine with dual roles in cancer biology, capable of exerting both tumor-promoting and tumor-suppressive effects. Acting through its receptor CX3CR1, CX3CL1 facilitates immune evasion, angiogenesis, metastasis, and tumor cell survival and proliferation by recruiting immunosuppressive myeloid-derived suppressor cells.
Robin Demuynck, Faye Naessens, Dmitri V. Krysko   +2 more
openaire   +2 more sources

Cancer cell death: Cell-autonomous and immunogenic dimensions

Cancer Cell
Regulated cell death (RCD) shapes neoplastic transformation, tumor progression, and response to treatment. While apoptosis was long viewed as the only RCD variant, additional modalities, including necroptosis, pyroptosis, and ferroptosis, have been characterized.
Lorenzo Galluzzi, Oliver Kepp, Laurence Zitvogel, Daolin Tang, Guido Kroemer   +4 more
openaire   +2 more sources

Natural modulators of the hallmarks of immunogenic cell death

Biochemical Pharmacology, 2019
Natural compounds act as immunoadjuvants as their therapeutic effects trigger cancer stress response and release of damage-associated molecular patterns (DAMPs). These reactions occur through an increase in the immunogenicity of cancer cells that undergo stress followed by immunogenic cell death (ICD).
Flavia Radogna, Mario Dicato, Marc Diederich   +2 more
openaire   +2 more sources

Methods to Detect Immunogenic Cell Death In Vivo

2019
In response to selected stressors, cancer cells can undergo a form of regulated cell death that-in immunocompetent syngeneic hosts-is capable of eliciting an adaptive immune response specific for dead cell-associated antigens. Thus, such variant of regulated cell death manifests with robust antigenicity and adjuvanticity.
Takahiro, Yamazaki, Aitziber, Buqué, Marissa, Rybstein, Jonathan, Chen, Ai, Sato, Lorenzo, Galluzzi   +5 more
openaire   +2 more sources

Anticancer metal drugs and immunogenic cell death

Journal of Inorganic Biochemistry, 2016
Conventional chemotherapeutics, but also innovative precision anticancer compounds, are commonly perceived to target primarily the cancer cell compartment. However, recently it was discovered that some of these compounds can also exert immunomodulatory activities which might be exploited to synergistically enhance their anticancer effects. One specific
Alessio Terenzi, Christine Pirker, Bernhard K. Keppler, Walter Berger   +3 more
openaire   +3 more sources

Targeting immunogenic cell death for glioma immunotherapy

Trends in Cancer
Immunogenic cell death (ICD) arouses great interest in targeting glioma, the most common primary brain tumor, to achieve boosted immunotherapy. We discuss the unexpected findings on the induction of Th17 immunity by ICD and propose the best design for dendritic cell (DC)-based vaccines loaded with whole glioma lysates obtained after ICD inducers.
Tatiana A. Mishchenko, Victoria D. Turubanova, Ekaterina N. Gorshkova, Olga Krysko, Maria V. Vedunova, Dmitri V. Krysko   +5 more
openaire   +2 more sources

Immunogenic Apoptotic Cell Death and Anticancer Immunity

2016
For many years it has been thought that apoptotic cells rapidly cleared by phagocytic cells do not trigger an immune response but rather have anti-inflammatory properties. However, accumulating experimental data indicate that certain anticancer therapies can induce an immunogenic form of apoptosis associated with the emission of damage-associated ...
Peter, Vandenabeele, Katrien, Vandecasteele, Claus, Bachert, Olga, Krysko, Dmitri V, Krysko   +4 more
openaire   +2 more sources